This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| start [2026/05/20 20:25] – [Categories] len | start [2026/06/08 05:33] (current) – len | ||
|---|---|---|---|
| Line 1: | Line 1: | ||
| ~~NOTOC~~ | ~~NOTOC~~ | ||
| ====== Patent News ====== | ====== Patent News ====== | ||
| + | |||
| + | |||
| + | ===== Supreme Court Narrows Inducement: Affirmative steps required (posted 06/08/26) ===== | ||
| + | |||
| + | In //{{ : | ||
| + | |||
| + | For Hatch-Waxman practice, the decision gives generic manufacturers more breathing room when marketing an FDA-approved generic for non-patented uses, especially where their statements reflect legal compliance, FDA-required labeling sameness, ordinary “generic equivalent” language, or standard industry practice. At the same time, the Court did not say skinny-label inducement claims are impossible; it emphasized that inducement can be express or implicit, but it must be clear, affirmative, | ||
| + | |||
| + | * [[lex> | ||
| + | * See also: //Cox Communications v. Sony Music Entertainment//, | ||
| ===== USPTO Guidance on subject matter eligibility declarations (SMEDs) (posted 02/09/26) ===== | ===== USPTO Guidance on subject matter eligibility declarations (SMEDs) (posted 02/09/26) ===== | ||